Real world study on elexacaftor ‐tezacaftor‐ivacaftor impact on cholesterol levels in adults with cystic fibrosis
ConclusionIn this real-world cohort of PwCF, cholesterol parameters increased after initiation with ETI therapy. Further consideration may need to be given for PwCF in regards to screening for cardiometabolic risk factors as PwCF age as well as the potential need for cholesterol-lowering therapies.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Kevin Lonabaugh,
Galvin Li,
Rhonda List,
Reyna Huang,
Amber James,
Andrew Barros,
Lindsay Somerville,
Dana Albon Tags: RESEARCH ARTICLE Source Type: research
More News: Cardiology | Cholesterol | Cystic Fibrosis | Drugs & Pharmacology | Heart | Statistics | Study